Company Analysis

Nurix Therapeutics, Inc. (NRIX)

Nasdaq: NRIX · Pharmaceutical Preparations · Brisbane, CA · filing with the SEC since 2012
Grade5.9
◀ Past 6.2● Present 5.7▶ Future 5.9
1 est.

Who runs Nurix Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Sands Arthur T
President, CEO. First filing Jul 2020, latest Feb 10, 2026, 0 filings in all.
Officers reporting now
4
of 12 people with a filing in the last fifteen months
Directors reporting now
8
20 people on the record since 2020
Officerssales are open-market, Nov 4, 2025 to Nov 4, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Van Houte HansChief Financial OfficerJul 2020Nov 4, 202611 · $700,000
Ring ChristineChief Legal OfficerJul 2020Nov 4, 202624 · $3.9M
Hansen GwennChief Scientific OfficerJul 2020Nov 2, 202612 · $800,000
Sands Arthur TPresident, CEOJul 2020Feb 10, 2026none
Directorssales are open-market, Nov 4, 2025 to Nov 4, 2026
NameRoleFirst filingLatest filingSales, 12 months
Gregory Julia PdirectorJul 2020Oct 14, 20261 · $500,000
Baynes Roy D.directorMar 2025May 15, 2026none
Dansey Roger DdirectorNov 2025May 15, 2026none
Kapur AnildirectorOct 2024May 15, 2026none
Lacey David L.directorJul 2020May 15, 2026none
Reinsdorf Judith AdirectorOct 2021May 15, 2026none
Saltzman Edward CdirectorSep 2022May 15, 2026none
Silva Paul MdirectorOct 2021May 15, 2026none
Earlier names on the record27, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton NRIX · research, not advice